ATE283703T1 - Neurodegenerative-erkrankung verwandtes gen - Google Patents

Neurodegenerative-erkrankung verwandtes gen

Info

Publication number
ATE283703T1
ATE283703T1 AT00907858T AT00907858T ATE283703T1 AT E283703 T1 ATE283703 T1 AT E283703T1 AT 00907858 T AT00907858 T AT 00907858T AT 00907858 T AT00907858 T AT 00907858T AT E283703 T1 ATE283703 T1 AT E283703T1
Authority
AT
Austria
Prior art keywords
neurodegenerative disorder
neurodegenerative disease
related gene
disease related
medicament
Prior art date
Application number
AT00907858T
Other languages
English (en)
Inventor
Roger Wayne Davies
Anthony Philip Payne
Roger Graham Sutcliffe
Original Assignee
Univ Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow filed Critical Univ Glasgow
Application granted granted Critical
Publication of ATE283703T1 publication Critical patent/ATE283703T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00907858T 1999-03-09 2000-03-09 Neurodegenerative-erkrankung verwandtes gen ATE283703T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9905218.5A GB9905218D0 (en) 1999-03-09 1999-03-09 Neurodegenerative disorder related gene
PCT/GB2000/000860 WO2000053218A1 (en) 1999-03-09 2000-03-09 Neurodegenerative disorder related gene

Publications (1)

Publication Number Publication Date
ATE283703T1 true ATE283703T1 (de) 2004-12-15

Family

ID=10849132

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00907858T ATE283703T1 (de) 1999-03-09 2000-03-09 Neurodegenerative-erkrankung verwandtes gen

Country Status (7)

Country Link
EP (1) EP1189631B1 (de)
JP (1) JP2003511346A (de)
AT (1) ATE283703T1 (de)
AU (1) AU2932100A (de)
DE (1) DE60016405T2 (de)
GB (1) GB9905218D0 (de)
WO (1) WO2000053218A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527209A (ja) 2002-04-22 2005-09-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛管理のためのプロテインキナーゼCγのペプチドインヒビター
US7655401B2 (en) * 2002-09-26 2010-02-02 University Of Washington Methods for identifying subjects susceptible to ataxic neurological disease
WO2005095983A1 (en) * 2004-03-04 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with protein kinase c, gamma (prkcg)
WO2013126963A1 (en) * 2012-02-29 2013-09-06 Benitec Biopharma Limited Pain treatment
US20190018000A1 (en) 2016-01-12 2019-01-17 Cedars-Sinai Medical Center A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
US11913022B2 (en) 2017-01-25 2024-02-27 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
EP4700387A2 (de) 2018-03-23 2026-02-25 Cedars-Sinai Medical Center Verfahren zur verwendung von inselzellen
WO2019195800A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Novel differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
WO2019195798A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Human pluripotent stem cell derived neurodegenerative disease models on a microfluidic chip
EP3787613B1 (de) * 2018-04-30 2026-03-11 Cedars-Sinai Medical Center Pkc-aktivierung zur verwendung bei der behandlung von sporadischer young onset parkinson-krankheit
DK4100060T3 (da) * 2020-02-06 2024-07-15 Perseus Science Group Llc Fremgangsmåde in vitro til diagnosticering af læsion i centralnervesystemet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
JPH06279311A (ja) * 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼcアイソザイムの活性化剤
US5922571A (en) * 1997-03-06 1999-07-13 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a protein kinase C homolog

Also Published As

Publication number Publication date
DE60016405D1 (de) 2005-01-05
DE60016405T2 (de) 2005-11-24
JP2003511346A (ja) 2003-03-25
AU2932100A (en) 2000-09-28
EP1189631B1 (de) 2004-12-01
GB9905218D0 (en) 1999-04-28
EP1189631A1 (de) 2002-03-27
WO2000053218A1 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
HUP0302332A2 (hu) Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére
DE60016405D1 (de) Neurodegenerative-erkrankung verwandtes gen
DE69429527D1 (de) Inhibitoren von beta-amyloid-protein-herstellung
ATE153704T1 (de) Anti-t-zell rezeptordeterminanten zur behandlung von autoimmunkrankheiten
DE60023936D1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
ATE302267T1 (de) Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
HUP9902571A2 (hu) Timidin kináz variánsai, ezeket kódoló nukleinsav-szekvenciák és alkalmazásuk génterápiában
EP1565581A4 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
DE69735545D1 (de) Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
DE69735436D1 (de) Methode zum nachweis von zell-apoptose
Fukui et al. Anti‐inflammatory protective effect of ADAMTS‐13 in murine arthritis models
MXPA02008239A (es) Gen humano de la esquizofrenia.
EP0756488A4 (de) Tumor-suppressor-gen und verfahren zum nachweis von krebs
CY1108568T1 (el) Αναστολεας για διαγνωση και θεραπεια ασθενων με αιμορροφιλια α
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
ATE466938T1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
DE69233263D1 (de) Nukleotidsequenzen und gegen cycloheximid resistente proteine
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
JP2003511346A5 (de)
MXPA02009781A (es) Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
GB9610281D0 (en) Diagnostic method and apparatus
NO955172L (no) Delesjonsvarianter av protein S med manglende C4BP-bindingsaktivitet, men med APC-kofaktoraktivitet, samt materiale og terapeutiske metoder
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE382637T1 (de) Rezeptor-tyrosine-kinase gene

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties